Phase II study of IRInotecan treatment after COmbined chemo ‐immunotherapy for extensive‐stage small cell lung cancer: Protocol of IRICO study

This study demonstrates and re-evaluates the clinical benefits of irinotecan after combined treatment with anti-PD-L1 and platinum-etoposide for patients with ES-SCLC.Registration detailsThis study was registered in the Japan Registry of Clinical Trials (no. jRCT s071210090) on November 4, 2021.

Source: Thoracic Cancer - September 7, 2023 Category: Cancer & Oncology Authors: Hiromi Tomono, Hirokazu Taniguchi, Minoru Fukuda, Takaya Ikeda, Seiji Nagashima, Kazumasa Akagi, Sawana Ono, Yasuhiro Umeyama, Midori Shimada, Hiroshi Gyotoku, Shinnosuke Takemoto, Yasushi Hisamatsu, Ryotaro Morinaga, Ryuta Tagawa, Ryosuke O Tags: STUDY PROTOCOL Source Type: research